The FDA granted breakthrough therapy designation to trastuzumab deruxtecan for second-line treatment of patients with metastatic HER2-positive breast cancer. The designation applies to use of the ...
FOSTER CITY, Calif., December 17, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
Auburn Memorial Hospital has gained a special designation that will enable the facility to improve patient services and continue on its path of profitability, a hospital official said today. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback